➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Merck
Harvard Business School

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,487,093


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,487,093
Title:.beta.-lactamase inhibitors
Abstract: Substituted bicyclic beta-lactams of Formula I: (I), are .beta.-lactamase inhibitors, wherein a, X, R.sup.1 and R.sup.2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with .beta.-lactam antibiotics. In particular, the compounds can be employed with a .beta.-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to .beta.-lactam antibiotics due to the presence of the .beta.-lactamases.
Inventor(s): Blizzard; Timothy A. (Princeton, NJ), Chen; Helen (Marlboro, NJ), Gude; Candido (Staten Island, NY), Hermes; Jeffrey D. (Warren, NJ), Imbriglio; Jason (Piscataway, NJ), Kim; Seongkon (Holmdel, NJ), Wu; Jane Y. (Marlboro, NJ), Mortko; Christopher J. (Hoboken, NJ), Mangion; Ian (Cranford, NJ), Rivera; Nelo (New Milford, NJ), Ruck; Rebecca T. (Jersey City, NJ), Shevlin; Michael (Plainfield, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/812,763
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,487,093

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI) ⤷  Try it Free
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) ⤷  Try it Free
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI) ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,487,093

PCT Information
PCT FiledJanuary 15, 2009PCT Application Number:PCT/US2009/031047
PCT Publication Date:July 23, 2009PCT Publication Number: WO2009/091856

International Family Members for US Patent 8,487,093

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009206119 ⤷  Try it Free
Brazil PI0906871 ⤷  Try it Free
Canada 2712783 ⤷  Try it Free
China 101918407 ⤷  Try it Free
China 102827067 ⤷  Try it Free
Colombia 6331438 ⤷  Try it Free
Costa Rica 11626 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.